Search research articles
Contact Us
Filters
Showing results (41-50 of 117) with videos related to
Page
of 12
Sort By:
Leukemia
|
May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)
Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
Blood Reviews
|
September 9, 2008
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
Antonio Palumbo, Meletios Dimopoulos, Jesus San Miguel, et al.
Lancet (London, England)
|
July 20, 2020
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, et al.
European Journal of Haematology
|
December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial
Fredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2002
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial
Paris Kosmidis, Nick Mylonakis, Costas Nicolaides, et al.
Cancer
|
June 22, 2010
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
Meletios Dimopoulos, Adrian Alegre, Edward A Stadtmauer, et al.
European Journal of Haematology
|
May 1, 2024
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
Maria-Victoria Mateos, Monika Engelhardt, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 20, 2011
How to manage neutropenia in multiple myeloma
Antonio Palumbo, Jon Bladé, Mario Boccadoro, et al.
British Journal of Haematology
|
February 16, 2017
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel
Shirley D'Sa, Marie José Kersten, Jorge J Castillo, et al.
BMC Cancer
|
April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 117) with videos related to
Sort By:
Page
of 12
Leukemia
|
May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)
Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
Blood Reviews
|
September 9, 2008
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
Antonio Palumbo, Meletios Dimopoulos, Jesus San Miguel, et al.
Lancet (London, England)
|
July 20, 2020
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, et al.
European Journal of Haematology
|
December 28, 2019
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial
Fredrik Schjesvold, Hartmut Goldschmidt, Vladimir Maisnar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2002
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial
Paris Kosmidis, Nick Mylonakis, Costas Nicolaides, et al.
Cancer
|
June 22, 2010
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
Meletios Dimopoulos, Adrian Alegre, Edward A Stadtmauer, et al.
European Journal of Haematology
|
May 1, 2024
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
Maria-Victoria Mateos, Monika Engelhardt, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 20, 2011
How to manage neutropenia in multiple myeloma
Antonio Palumbo, Jon Bladé, Mario Boccadoro, et al.
British Journal of Haematology
|
February 16, 2017
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel
Shirley D'Sa, Marie José Kersten, Jorge J Castillo, et al.
BMC Cancer
|
April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
Page
of 12